G-PUR® for Reduced Lead Bioavailability

See also
Status	Clinical Trial	Phase
Completed	`NCT00283647` - MR Assessment of Brain Function Altered by Lead Exposure	N/A
Completed	`NCT00342849` - Treatment of Lead-Exposed Children Trial	Phase 3
Enrolling by invitation	`NCT05887934` - Bone-Lead Level Associations With Brain and Mental Health

See also

Status

Clinical Trial

Phase

Completed

NCT00283647 - MR Assessment of Brain Function Altered by Lead Exposure

N/A

Completed

NCT00342849 - Treatment of Lead-Exposed Children Trial

Phase 3

Enrolling by invitation

NCT05887934 - Bone-Lead Level Associations With Brain and Mental Health

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04138693
Study type	Interventional
Source	Glock Health, Science and Research GmbH
Contact
Status	Completed
Phase	N/A
Start date	September 24, 2019
Completion date	February 12, 2020

G-PUR® for Reduced Lead Bioavailability

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms